Cidara Therapeutics rises after EU regulator backs antifungal drug

Cidara Therapeutics

13/10/2023 16:32

** Shares of drug developer Cidara Therapeutics Inc  CDTX.O 
up 1.2% at $0.93
    ** Co says EU regulator's Committee for Medicinal Products
for Human Use adopted a positive opinion for marketing
application of its drug rezafungin
     ** Co is seeking EU approval for the drug to treat adults
with a type of yeast infection called invasive candidiasis, in
adults, that spread through the bloodstream
    ** CHMP's positive opinion based on results from the pivotal
late-stage trial, which demonstrated statistical non-inferiority
for rezafungin, dosed once weekly vs the current standard of
care, dosed once daily - co
    ** Rezafungin, branded as Rezzayo, was approved by the U.S.
health regulator in March to treat a group of severe fungal
infections that are most commonly faced by hospitalized patients
    ** CDTX has partnered with healthcare co Mundipharma, which
has commercial rights to rezafungin outside the U.S. and Japan
    ** Including session's moves, stock up ~22% YTD
     

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))